Onco Wiki / Drogue

Docetaxel

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDRUG-DOCETAXEL
TypeMédicament
Alias
Le Président. - Merci.DocétéreTaxotéreДоцетаксель
Étatreviewed 2026-04-26 | pending_clinical_signoff
MaladiesDIS-BREAST DIS-CRC DIS-ESOPHAGEAL DIS-GASTRIC DIS-NSCLC DIS-PROSTATE DIS-SOFT-TISSUE-SARCOMA
SourcesSRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025

Faits sur les drogues

CatégorieTaxane (stabilisateur de microtubules)
MécanismeSemi-synthetic taxane derived from European yew (Taxus baccata). Binds the β-subunit of polymerized tubulin at the taxane-binding site (~1.9× higher affinity than paclitaxel), promoting microtubule assembly and stabilizing existing microtubules against depolymerization. Cells arrest at G2/M, triggering apoptosis. Solubilized in polysorbate 80 (Tween 80) + ethanol — premedication with corticosteroids critical to prevent fluid retention and hypersensitivity (Cremophor-EL not used in docetaxel). Higher myelosuppression and febrile neutropenia rates than paclitaxel.
Dose typiqueProstate (mHSPC + mCRPC): 75 mg/m² IV q3 weeks × 6 cycles (mHSPC, CHAARTED) or × 10 cycles (mCRPC, TAX-327, until intolerance). Breast adjuvant TAC: 75 mg/m² IV day 1 q21d × 6 (with doxorubicin 50 mg/m² + cyclophosphamide 500 mg/m²). Breast metastatic mono: 60-100 mg/m² IV q21d. NSCLC 2L mono: 75 mg/m² IV q21d. NSCLC 1L (with cisplatin): 75 mg/m² IV q21d. Gastric DCF: 75 mg/m² IV day 1 q21d (with cisplatin + 5-FU). Head and neck TPF induction: 75 mg/m² IV day 1 q21d × 3 (with cisplatin + 5-FU). Mandatory premedication: dexamethasone 8 mg PO BID × 3 days starting day before infusion (to prevent fluid retention and hypersensitivity).
Ukraine enregistréeVrai
NSZU rembourséVrai
Ukraine vérifiée pour la dernière fois2026-04-27

Avertissements

Notes

Cytotoxic backbone added to ADT for high-volume mHSPC (CHAARTED, STAMPEDE) and as ARASENS triplet partner with darolutamide. mCRPC option (TAX-327) but ARPIs typically preferred 1L if no high-volume burden. Hepatic adjustment essential — bilirubin > ULN requires dose reduction or avoidance. Premedication: dexamethasone 8 mg PO BID × 3 days starting day before to prevent fluid retention + hypersensitivity. G-CSF primary prophylaxis for high febrile- neutropenia risk regimens (TAC, TPF, DCF). Cumulative neuropathy + nail toxicity may be dose-limiting after several cycles.

Utilisé par

Protocole thérapeutique